Preventive systemic administration of DRD2 agonists has the potential to delay the progression of high-risk intermediate AMD patients to nAMD and to reduce their continuous need for repeated intravitreal anti-VEGF injections. This evidence concerns the gene VEGFA and age-related macular degeneration.